The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.

Viardot, A., Locatelli, F., Stieglmaier, J., Zaman, F., Jabbour, E., Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies, <<ANNALS OF HEMATOLOGY>>, 2020; 99 (10): 2215-2229. [doi:10.1007/s00277-020-04221-0] [https://hdl.handle.net/10807/228474]

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

Locatelli, Franco
Secondo
Writing – Review & Editing
;
2020

Abstract

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblastic leukemia and B cell precursor acute lymphoblastic leukemia with minimal residual disease. Blinatumomab is also being evaluated in combination with other agents (tyrosine kinase inhibitors, checkpoint inhibitors, and chemotherapy) in various treatment settings, including frontline protocols. An extended half-life BiTE molecule is also under investigation. Patients receiving blinatumomab may experience cytokine release syndrome and neurotoxicity; however, these events may be less frequent and severe than in patients receiving other CD19-targeted immunotherapies, such as chimeric antigen receptor T cell therapy. We review BiTE technology for treating malignancies that express CD19, analyzing the benefits and limitations of this bispecific T cell engager platform from clinical experience with blinatumomab.
2020
Inglese
Viardot, A., Locatelli, F., Stieglmaier, J., Zaman, F., Jabbour, E., Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies, <<ANNALS OF HEMATOLOGY>>, 2020; 99 (10): 2215-2229. [doi:10.1007/s00277-020-04221-0] [https://hdl.handle.net/10807/228474]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/228474
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 24
social impact